Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Prostate Cancer Pipeline Drugs Market Overview

Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction.

The Prostate Cancer pipeline drugs market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects.

Prostate Cancer Pipeline Drugs Market Segmentation by Targets

The key targets in the Prostate Cancer pipeline drugs market are Androgen Receptor, Cells Expressing Glutamate Carboxypeptidase 2, Poly [ADP Ribose] Polymerase 1, Tubulin, Gonadotropin Releasing Hormone Receptor, CD3, Programmed Cell Death Protein 1, Poly [ADP Ribose] Polymerase 2, Cytotoxic T Lymphocyte Protein 4, and Programmed Cell Death 1 Ligand 1, among others. Androgen Receptor was the leading target in the pipeline.

Prostate Cancer Pipeline Drugs Market Analysis by Targets

Prostate Cancer Pipeline Products Market Analysis by Targets

For more target insights into the Prostate Cancer pipeline products market, download a free report sample

Prostate Cancer Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Prostate Cancer pipeline products market are Cytotoxic To Cells Expressing Glutamate Carboxypeptidase 2, Androgen Receptor Antagonist, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Tubulin Inhibitor, CD3 Agonist, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, Programmed Cell Death Protein 1 Antagonist, Androgen Receptor Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, and Gonadotropin Releasing Hormone Receptor Agonist, among others. Cytotoxic To Cells Expressing Glutamate Carboxypeptidase 2 was the leading MoA in the pipeline market.

Prostate Cancer Pipeline Products Market Analysis by Mechanisms of Action

Prostate Cancer Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Prostate Cancer pipeline products market, download a free report sample

Prostate Cancer Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Prostate Cancer pipeline products market are oral, intravenous, subcutaneous, intratumor, parenteral, intramuscular, intradermal, intravesical, intravenous drip, and intraperitoneal, among others. Oral was the most preferred route.

Prostate Cancer Pipeline Products Market Analysis by Routes of Administration

Prostate Cancer Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Prostate Cancer pipeline products market, download a free report sample

Prostate Cancer Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Prostate Cancer pipeline drugs market are small molecule, monoclonal antibody, monoclonal antibody conjugated, gene-modified cell therapy, synthetic peptide, subunit vaccine, fusion protein, oncolytic virus, recombinant vector vaccine, and cell therapy, among others. Small molecule was the leading molecule in the pipeline.

Prostate Cancer Pipeline Drugs Market Analysis by Molecule Types

Prostate Cancer Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Prostate Cancer pipeline products market, download a free report sample

Prostate Cancer Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Prostate Cancer pipeline products market are Sathgen Biotech, AstraZeneca Plc, Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc, Jiangsu Hengrui Medicine Co Ltd, Hinova Pharmaceuticals Co Ltd, Novartis AG, GSK plc, and ImmunityBio Inc. Sathgen Biotech is the leading company in the Prostate Cancer pipeline products market.

Prostate Cancer Pipeline Products Market Analysis by Companies

Prostate Cancer Pipeline Products Market Analysis by Companies

To know more about the leading players in the Prostate Cancer pipeline products market, download a free report sample

Prostate Cancer Pipeline Products Market Report Overview

Key Targets Androgen Receptor, Cells Expressing Glutamate Carboxypeptidase 2, Poly [ADP Ribose] Polymerase 1, Tubulin, Gonadotropin Releasing Hormone Receptor, CD3, Programmed Cell Death Protein 1, Poly [ADP Ribose] Polymerase 2, Cytotoxic T Lymphocyte Protein 4, and Programmed Cell Death 1 Ligand 1
Key Mechanisms of Action Cytotoxic To Cells Expressing Glutamate Carboxypeptidase 2, Androgen Receptor Antagonist, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Tubulin Inhibitor, CD3 Agonist, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, Programmed Cell Death Protein 1 Antagonist, Androgen Receptor Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, and Gonadotropin Releasing Hormone Receptor Agonist
Key Routes of Administration Oral, Intravenous, Subcutaneous, Intratumor, Parenteral, Intramuscular, Intradermal, Intravesical, Intravenous Drip, and Intraperitoneal
Key Molecule Type Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Synthetic Peptide, Subunit Vaccine, Fusion Protein, Oncolytic Virus, Recombinant Vector Vaccine, and Cell Therapy
Leading Companies Sathgen Biotech, AstraZeneca Plc, Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc, Jiangsu Hengrui Medicine Co Ltd, Hinova Pharmaceuticals Co Ltd, Novartis AG, GSK plc, and ImmunityBio Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

3D Medicines Inc
4D Pharma Plc
4SC AG
A28 Therapeutics Inc
Aavocyte Inc
Abbisko Cayman Limited
AbbVie Inc
Abion Inc
Accro Bioscience Suzhou Co Ltd
Accutar Biotechnology Inc
Acrotech Biopharma LLC
Actinium Pharmaceuticals Inc
Actuate Therapeutics Inc
ADC Therapeutics SA
Adicet Bio Inc
Advanced Accelerator Applications SA
AdvanCell Isotopes Pty Ltd
Advaxis Inc
Advenchen Laboratories LLC
Adze Biotechnology Inc
Agenus Inc
AIkido Pharma Inc
AilseVax Ltd
AIM ImmunoTech Inc
Akeso Inc
Alessa Therapeutics Inc
Alla Chem LLC
Allife Medical Science and Technology Co Ltd
Alligator Bioscience AB
Almac Discovery Ltd
AlphaMab Co Ltd
Alphamab Oncology
Alpine Immune Sciences Inc
Altay Therapeutics Inc
Ambrx Biopharma Inc
American Gene Technologies International Inc
Amgen Inc
Amphivena Therapeutics Inc
Anagenics Ltd
Anavex Life Sciences Corp
Andes Biotechnologies
AnGes Inc
Anhorn Medicines Co Ltd
ANP Technologies Inc
Antapodia Therapeutics Inc
Antares Pharma Inc
Antev Ltd
AntiCancer Inc
Antikor Biopharma Ltd
Apcure SAS
Apexian Pharmaceuticals Inc
Aphios Corp
APIM Therapeutics AS
Aprilbio Co Ltd
Aptevo Therapeutics Inc
Aqualung Therapeutics Corp
Aranda Pharma Ltd
Arch Oncology Inc
Arcus Biosciences Inc
Ariz Precision Medicine Inc
Artelo Biosciences Inc
Arvinas Inc
Ascelia Pharma AB
Ascentage Pharma Group Inc
Ascentawits Pharmaceuticals Ltd
Asieris Pharmaceuticals Co Ltd
AskAt Inc
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Atreca Inc
Aucentra Therapeutics Pty Ltd
AUM Biosciences Pte Ltd
Auransa Inc
Aurigene Discovery Technologies Ltd
Austhera BioSciences Inc
Autolus Therapeutics Plc
AvenCell Europe GmbH
Avican Inc
Avivia BV
b3 bio Inc (Inactive)
Bantam Pharmaceutical LLC
Basilea Pharmaceutica Ltd
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing Biostar Technologies Ltd
Bellicum Pharmaceuticals Inc
Betta Pharmaceuticals Co Ltd
Better Life Pharmaceuticals Inc
Bexion Pharmaceuticals LLC
Bicycle Therapeutics Plc
Bika Biotechnology Guanzhou Co Ltd
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Bio-Synectics Inc
Bio-Thera Solutions Ltd
BioAtla Inc
BioCurity Pharmaceuticals Inc
BioEclipse Therapeutics Inc
Biohaven Pharmaceutical Holding Company Ltd
Biokine Therapeutics Ltd
Biolexis Therapeutics Inc
BioNTech SE
Biopep Solutions Inc
Biosceptre International Ltd
Biosplice Therapeutics Inc
Bioven Group
BioVie Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Bukwang Pharmaceutical Co Ltd
Calidi Biotherapeutics Inc
Calidum Inc
Calithera Biosciences Inc
Camurus AB
Can-Fite BioPharma Ltd
Cancer Targeted Technology LLC
Candel Therapeutics Inc
Canget BioTekpharma LLC
Cardiff Oncology Inc
Carina Biotech Pty Ltd
Carrick Therapeutics Ltd
CAS-Lamvac Biotech Co Ltd
Celcuity Inc
Cellbion Co Ltd
CellCentric Ltd
Celldex Therapeutics Inc
Cellid Co Ltd
Cello Therapeutics Inc
Cells for Cells SA
CellVax Therapeutics Inc
Celprogen Inc
Celtek Bioscience LLC
ChemRegen Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chimerix Inc
Chong Kun Dang Pharmaceutical Corporation
Clarity Pharmaceuticals Ltd
Cloaked Therapeutics LLC
Clovis Oncology Inc
CMG Pharmaceutical Co Ltd
CNBX Pharmaceuticals Inc
Codagenix Inc
CohBar Inc
Coherent Biopharma
Context Therapeutics Inc
Convalife
Convergent Therapeutics Inc
Corcept Therapeutics Inc
Corvus Pharmaceuticals Inc
Cosmo Pharmaceuticals NV
Cothera Bioscience Pty Ltd
Crescendo Biologics Ltd
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Cue Biopharma Inc
Curadis GmbH
Curasight
CureLab Oncology Inc
CureMeta LLC
Curigin Co Ltd
Curium Midco Sarl
Curve Therapeutics Ltd
Cyclacel Pharmaceuticals Inc
CytoImmune Therapeutics Inc
CytomX Therapeutics Inc
CZ BioMed Corp
Da Zen Theranostics Inc
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
DEKK-TEC Inc
DevaCell Inc
DexTech Medical AB
Diakonos Research Ltd
Disulfican Ltd
Divide and Conquer Ltd
DNJ Pharma Inc
Dracen Pharmaceuticals Inc
Duet Therapeutics Inc
Duo Oncology Inc
Ectin Research AB
Eisai Co Ltd
Elevation Oncology Inc
Eli Lilly and Co
Ellipses Pharma Ltd
Emtora Biosciences
Enara Bio Ltd
Enceladus Pharmaceuticals BV
Endoceutics Inc
Ennaid Therapeutics LLC
EntreChem SL
EOS Biosciences Inc
EpiAxis Therapeutics Pty Ltd
EpicentRx Inc
Epigene Therapeutics Inc
EpimAb Biotherapeutics Inc
Epizyme Inc
Esanex Inc
ESSA Pharma Inc
EstryX Pharma Ltd
Etern BioPharma Co Ltd
Eternity Bioscience Inc
Eurofarma Laboratorios SA
Evgen Pharma Plc
Exelixis Inc
ExonanoRNA LLC
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Felicitex Therapeutics Inc
Fog Pharmaceuticals Inc
For-Robin Inc
Foresee Pharmaceuticals Co Ltd
Forma Therapeutics Inc
Fortis Therapeutics Inc
Fujifilm Holdings Corp
Fusion Pharmaceuticals Inc
Future Medicine Co Ltd
FutureChem Co Ltd
G1 Therapeutics Inc
Galectin Therapeutics Inc
GemVax & KAEL Co Ltd
Genelux Corp
Genentech USA Inc
Geneos Therapeutics Inc
Genetic Immunity Inc
GenFleet Therapeutics (Shanghai) Inc
GenKyoTex SA
Genmab AS
GeoVax Labs Inc
Gilead Sciences Inc
Glactone Pharma AB
GLG Pharma SA
Glycomantra Inc
GlycoMimetics Inc
GlycoNex Inc
GlyTech Inc
GlyTherix Ltd
GO Therapeutics Inc
Greenfire Bio LLC
GSK plc
GT Biopharma Inc
Guangzhou Doublle Bioproduct Inc
HaimBio Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harpoon Therapeutics Inc
HCW Biologics Inc
Health Ever Bio-Tech Co Ltd
Heidelberg Pharma AG
Helixmith Co Ltd
Hinova Pharmaceuticals Co Ltd
Hookipa Pharma Inc
HOX Therapeutics Ltd
Hualan Biological Engineering Inc
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
IC-MedTech Inc
Idience Co Ltd
Ildong Pharmaceutical Co Ltd
ImaginAb Inc
ImCheck Therapeutics SAS
Immix BioPharma Inc
Immune Biosolutions Inc
Immune Pharmaceuticals Inc
Immunic Inc
ImmunityBio Inc
Immunogenesis Inc
ImmunSYS Inc
IMPACT Therapeutics Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Inmune Bio Inc
InnoCare Pharma Ltd
Innocrin Pharmaceuticals Inc
Innovative Cellular Therapeutics Co Ltd
Innovimmune Biotherapeutics Inc
Inovio Pharmaceuticals Inc
Inserm Transfert SA
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
Isoprene Pharmaceuticals Inc
iTeos Therapeutics Inc
ITM Isotope Technologies Munich SE
Jacobio Pharmaceuticals Group Co Ltd
Janux Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu ProteLight Pharmaceutical & Biotechnology Co Ltd
Jina Pharmaceuticals Inc
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Therapeutics Inc
JW Pharmaceutical Corp
Jyant Technologies Inc
Kalos Therapeutics Inc
Kangpu Biopharmaceuticals Ltd
Karyopharm Therapeutics Inc
Kezar Life Sciences Inc
Kinnate Biopharma Inc
Kintor Pharmaceutical Ltd
Komipharm International Co Ltd
KOP Therapeutics Corp
Kringle Pharma Inc
Kronos Bio Inc
KYAN Therapeutics Inc
Laekna Therapeutics Shanghai Co Ltd
Lantern Pharma Inc
LATITUDE Pharmaceuticals Inc
LAVA Therapeutics NV
Leap Therapeutics Inc
Lidds AB
Liminal BioSciences Inc
Lipo-Immuno Tech LLC
LipoSeuticals Inc
Livzon Pharmaceutical Group Co Ltd
Luminus Biosciences Inc
Luye Pharma Group Ltd
Lycotec Ltd
Lyvgen Biopharma Ltd
MacroGenics Inc
Madison Vaccines Inc
MAIA Biotechnology Inc
Marengo Therapeutics Inc
Matrix Biomed Inc
MaxiVAX SA
Mayne Pharma Group Ltd
Meabco AS
Med Discovery SA
MedAnnex Ltd
MediaPharma SRL
Medigen Inc
MediGene AG
MedinCell SA
Mediolanum farmaceutici SpA
Medolife Rx Inc
MedPacto Inc
Merck & Co Inc
Merck KGaA
Merus NV
MesaGen LLC
Metacurum Biotech AB
MetasTx LLC
MetCure Therapeutics LLC
MGC Pharmaceuticals Ltd
Midissia Therapeutics Inc
Minerva Biotechnologies Corp
MiNK Therapeutics Inc
Mithra Pharmaceuticals SA
Modra Pharmaceuticals BV
Molecular Partners AG
Molecular Templates Inc
Momotaro-Gene Inc
MorphoSys AG
Multitude therapeutics Inc
Mustang Bio Inc
Myrio Therapeutics Pty Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanocan Therapeutics Corp
Nanogenics Ltd
Nanology LLC
National Medical Research Center of Radiology
Natsar Pharmaceuticals Inc
NeoTX Therapeutics Ltd
Nerviano Medical Sciences SRL
NewBay Medical Technology Co Ltd
NewG Lab Pharma Inc
NextCure Inc
NGM Biopharmaceuticals Inc
Novartis AG
Novelogics Biotechnology Inc
Noxopharm Ltd
Nuage Therapeutics SL
NucleoBio Inc
NuGenerex Immuno-Oncology Inc
Nurix Therapeutics Inc
Nutshell Therapeutics Inc
Nuvation Bio Inc
Nymox Pharmaceutical Corp
Ohana Vaccine LLC
Omeros Corp
Ona Therapeutics SL
OncoFusion Therapeutics Inc
Oncomatryx Biopharma SL
Onconic Therapeutics Co Ltd
OncoOne Research & Development GmbH
OncoQuest Inc
Oncorus Inc
OncoTartis Inc
Oncotelic Therapeutics Inc
OncoTherapy Science Inc
OncoTherics Ltd
Oncternal Therapeutics
Oneness Biotech Co Ltd
Ono Pharmaceutical Co Ltd
Onxeo SA
OPKO Health Inc
Orano Med LLC
ORCA Therapeutics BV
ORIC Pharmaceuticals Inc
Orion Corp
Otsuka Pharmaceutical Co Ltd
Oxford Vacmedix UK Ltd
Pact Pharma Inc
Pahan Therapeutics
Palisades Therapeutics
Panacela Labs Inc
Panbela Therapeutics Inc
Pandomedx Inc
Pantarhei Oncology BV
Parabon NanoLabs Inc
PDS Biotechnology Corp
Pellficure Pharmaceuticals Inc
PendreaBio Inc
Penzymes LLC
PepVax Inc
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
Pharmadrug Inc
Pharmicell Co Ltd
pHion Therapeutics Ltd
Phoenix Molecular Designs
Pimera Inc
Plexium Inc
Plus Therapeutics Inc
POINT Biopharma Global Inc
Polaris Pharmaceuticals Inc
Polyplus-Transfection SA
Portage Biotech Inc
Poseida Therapeutics Inc
Potenza Therapeutics Inc
Praesidia Biotherapeutics Inc
Precision Molecular Inc
Prelude Therapeutics Inc
Primary Peptides Inc
PRISM Pharma Co Ltd
ProDa BioTech LLC
Progenics Pharmaceuticals Inc
Promontory Therapeutics Inc
Propanc Biopharma Inc
Propella Therapeutics Inc
Proteovant Therapeutics Inc
Protheragen Inc
Puma Biotechnology Inc
Purple Biotech Ltd
QED Therapeutics Inc
Qilu Pharmaceutical Co Ltd
Qu Biologics Inc
Quadriga BioSciences Inc
Qualigen Therapeutics Inc
Que Oncology Inc
QurCan Therapeutics Inc
Qurient Co Ltd
Qwixel Therapeutics LLC
Radiomedix Inc
Radiopharm Theranostics Ltd
Rasayani Biologics Pvt Ltd
Ratio Therapeutics Inc
Recordati SpA
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Reglagene Holding Inc
Regulaxis SAS
Replicate Bioscience Inc
Res Nova Bio Inc
Revere Pharmaceuticals Inc
RheinCell Therapeutics GmbH
Rhizen Pharmaceuticals SA
Riptide Bioscience Inc
Roivant Sciences Ltd
RS Research
Rubicon Biotechnology Inc
Ryvu Therapeutics SA
Sagimet Biosciences Inc
Salarius Pharmaceuticals Inc
Samyang Biopharmaceuticals Corp
San Rocco Therapeutics LLC
Sanofi
Sapience Therapeutics Inc
Sathgen Biotech
Seagen Inc
Seagull BioSolutions Pvt Ltd
Semorex Inc
Senex Biotechnology
Senhwa Biosciences Inc
Serene LLC
Seven and Eight Biopharmaceuticals Corp
Shanghai Bioray Laboratory Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Huilun Life Science & Technology Co Ltd
Shanghai Humantech Biotechnology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shanghai Yihao Biotechnology Co Ltd
Shanghai Yuyao Biotechnology Ltd
Shenogen Pharma Group Ltd
Shijiazhuang No. 4 Pharmaceutical Co Ltd
Sichuan Huiyang Life Science and Technology Corp
Siege Pharmaceuticals Inc
SignPath Pharma Inc
Silenseed Ltd
Sillajen Biotherapeutics
Singh Biotechnology LLC
Sino Biopharmaceutical Ltd
SiNOPSEE Therapeutics Pte Ltd
Siragen Pharmaceuticals Inc
Sisu Pharma Inc
SL VaxiGen Inc
Smerud Medical Research International AS
SN BioScience
Socium Inc
Socium Therapeutics Inc
Sonnet BioTherapeutics Holdings Inc
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Sosei Group Corp
SOTIO Biotech AS
Spexis AG
Splash Pharmaceuticals Inc
Starpharma Holdings Ltd
Stcube Inc
Sumitomo Dainippon Pharma Oncology, Inc
Suzhou Innovative Biomaterials & Pharmaceutics Co Ltd
Suzhou Medilink Therapeutics Ltd
Suzhou Ribo Life Sciences Co Ltd
Syncromune Inc
SynDevRx Inc
Syntrix Pharmaceuticals
Tactical Therapeutics Inc
TAE Life Sciences LLC
Taiho Oncology Inc
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Takis Srl
Tango Therapeutics Inc
TargaGenix Inc
TargImmune Therapeutics AG
Targovax ASA
Tavanta Therapeutics Inc
Telix Pharmaceuticals Ltd
Tempest Therapeutics Inc
Teon Therapeutics Inc
Tetranov International Inc
Teva Pharmaceutical Industries Ltd
Tevogen Bio Inc
The National Institute for Biotechnology in the Negev Ltd
Theranano LLC
TheraTarget Inc
Theratechnologies Inc
Theravectys SA
Thryv Therapeutics Inc
TiumBio Co Ltd
Tiziana Life Sciences Plc
Tmunity Therapeutics Inc
TOLREMO Therapeutics AG
TRACON Pharmaceuticals Inc
Transcenta Holding Ltd
TransThera Sciences (Nanjing) Inc
Treadwell Therapeutics Inc
TREAT U SA
TRIM-edicine Inc
Turnstone Biologics Inc
TVAX Biomedical Inc
Twinpigbiolab Co Ltd
Tyg Oncology Ltd
Tyme Inc
UbiVac Inc
UCB SA
Ultimovacs AS
Up Therapeutics Inc
UroGen Pharma Ltd
UTC Therapeutics Inc
Vaccitech Plc
ValiRx Plc
Valiseek Ltd
Vasgen Ltd
VasGene Therapeutics Inc
Vault Pharma Inc
VaxCell Biotherapeutics Co Ltd
Vaxon Biotech
Venus Remedies Ltd
Verastem Inc
Veru Inc
Vincerx Pharma Inc
Virocure Inc
Vitanova Biomedical Inc
Vittail Ltd
Vivesto AB
VLP Therapeutics LLC
VM Discovery Inc
Vortex Biotechnology Corp
Walking Fish Therapeutics Inc
Werewolf Therapeutics Inc
WntResearch AB
Wuxi Jesse Pharmaceutical Co Ltd
Xbrane Biopharma AB
XEME BioPharma Inc
Xencor Inc
Xenimmune
Xiangxue Life Sciences
Xiconic Pharmaceuticals LLC
XinThera Inc
Y-mAbs Therapeutics Inc
Yisheng Biopharma Co Ltd
Zenith Epigenetics Ltd
Zenopharm LLC
Zhejiang Conba Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zhuhai Beihai Biotech Co Ltd
Zumutor Biologics Inc
Zy Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Prostate Cancer – Overview

Prostate Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Prostate Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostate Cancer – Companies Involved in Therapeutics Development

Prostate Cancer – Drug Profiles

Prostate Cancer – Dormant Projects

Prostate Cancer – Discontinued Products

Prostate Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Prostate Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Number of Products by Stage and Molecule Type, 2022 (Contd..1)

Prostate Cancer – Dormant Projects, 2022

Prostate Cancer – Dormant Projects, 2022 (Contd..1)

Prostate Cancer – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Prostate Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Prostate Cancer pipeline products market?

    The key targets in the Prostate Cancer pipeline products market are Androgen Receptor, Cells Expressing Glutamate Carboxypeptidase 2, Poly [ADP Ribose] Polymerase 1, Tubulin, Gonadotropin Releasing Hormone Receptor, CD3, Programmed Cell Death Protein 1, Poly [ADP Ribose] Polymerase 2, Cytotoxic T Lymphocyte Protein 4, and Programmed Cell Death 1 Ligand 1, among others.

  • What are the key mechanisms of action in the Prostate Cancer pipeline products market?

    The key mechanisms of action in the Prostate Cancer pipeline products market are Cytotoxic To Cells Expressing Glutamate Carboxypeptidase 2, Androgen Receptor Antagonist, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Tubulin Inhibitor, CD3 Agonist, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, Programmed Cell Death Protein 1 Antagonist, Androgen Receptor Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, and Gonadotropin Releasing Hormone Receptor Agonist, among others.

  • What are the key routes of administration in the Prostate Cancer pipeline products market?

    The key routes of administration in the Prostate Cancer pipeline products market are oral, intravenous, subcutaneous, intratumor, parenteral, intramuscular, intradermal, intravesical, intravenous drip, and intraperitoneal, among others.

  • What are the key molecule types in the Prostate Cancer pipeline products market?

    The key molecule types in the Prostate Cancer pipeline products market are small molecule, monoclonal antibody, monoclonal antibody conjugated, gene-modified cell therapy, synthetic peptide, subunit vaccine, fusion protein, oncolytic virus, recombinant vector vaccine, and cell therapy, among others.

  • Which are the leading companies in the Prostate Cancer pipeline products market?

    Some of the leading companies in the Prostate Cancer pipeline products market are Sathgen Biotech, AstraZeneca Plc, Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc, Jiangsu Hengrui Medicine Co Ltd, Hinova Pharmaceuticals Co Ltd, Novartis AG, GSK plc, and ImmunityBio Inc.

Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.